Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Aug, 2016 | Pages:
233 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Dementia - Pipeline Review, H2 2016 Summary Global Markets Direct's, 'Dementia - Pipeline Review, H2 2016', provides an overview of the Dementia pipeline landscape. The report provides comprehensive information on the therapeutics under development for Dementia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Dementia and features dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the global therapeutic landscape of Dementia - The report reviews pipeline therapeutics for Dementia by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved Dementia therapeutics and enlists all their major and minor projects - The report assesses Dementia therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news related to pipeline therapeutics for Dementia Reasons to buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand important and diverse types of therapeutics under development for Dementia - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Dementia pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2 List of Tables 6 List of Figures 8 Introduction 9 Global Markets Direct Report Coverage 9 Dementia Overview 10 Therapeutics Development 11 Pipeline Products for Dementia - Overview 11 Pipeline Products for Dementia - Comparative Analysis 12 Dementia - Therapeutics under Development by Companies 13 Dementia - Therapeutics under Investigation by Universities/Institutes 16 Dementia - Pipeline Products Glance 17 Late Stage Products 17 Clinical Stage Products 18 Early Stage Products 19 Unknown Stage Products 20 Dementia - Products under Development by Companies 21 Dementia - Products under Investigation by Universities/Institutes 25 Dementia - Companies Involved in Therapeutics Development 26 Adamas Pharmaceuticals, Inc. 26 AgeneBio Inc. 27 Alector LLC 28 AlzProtect SAS 29 Amarantus Bioscience Holdings, Inc. 30 Anavex Life Sciences Corp. 31 Axon Neuroscience SE 32 Axovant Sciences Ltd. 33 BioArctic Neuroscience AB 34 Biogen Inc 35 Biotie Therapies Corp. 36 Boehringer Ingelheim GmbH 37 Chase Pharmaceuticals Corporation 38 Cortice Biosciences, Inc. 39 Daewoong Pharmaceutical Co., Ltd. 40 Eisai Co., Ltd. 41 Eli Lilly and Company 42 FORUM Pharmaceuticals Inc. 43 H. Lundbeck A/S 44 Heptares Therapeutics Limited 45 Hyundai Pharmaceutical Co., Ltd. 46 Ildong Pharmaceutical Co., Ltd. 47 Immungenetics AG 48 ImStar Therapeutics Inc. 49 Integrative Research Laboratories Sweden AB 50 Intellect Neurosciences, Inc. 51 Intra-Cellular Therapies, Inc. 52 INVENT Pharmaceuticals, Inc. 53 M3 Biotechnology, Inc. 54 MediPost Co., Ltd. 55 Neuraltus Pharmaceuticals, Inc. 56 Neurimmune Holding AG 57 Neurodyn Inc. 58 Oryzon Genomics SA 59 Otsuka Holdings Co., Ltd. 60 P2D Bioscience 61 Pacific Northwest Biotechnology, LLC 62 Pivot Pharmaceuticals Inc 63 Sinil Pharmaceutical Co., Ltd 64 Stelic Institute & Co., Inc. 65 Sumitomo Dainippon Pharma Co., Ltd. 66 Sylentis S.A.U. 67 Takeda Pharmaceutical Company Limited 68 TauRx Therapeutics Ltd. 69 Voyager Therapeutics, Inc. 70 WhanIn Pharmaceutical Co., Ltd. 71 Zhejiang Hisun Pharmaceutical Co., Ltd. 72 Dementia - Therapeutics Assessment 73 Assessment by Monotherapy Products 73 Assessment by Combination Products 74 Assessment by Target 75 Assessment by Mechanism of Action 78 Assessment by Route of Administration 81 Assessment by Molecule Type 83 Drug Profiles 85 (donepezil hydrochloride + memantine hydrochloride ER) - Drug Profile 85 (donepezil hydrochloride + solifenacin succinate) - Drug Profile 87 AADvac-1 - Drug Profile 88 AD-35 - Drug Profile 89 ANAVEX-371 - Drug Profile 90 Antisense RNAi Oligonucleotide for Cerebral Ischemia and Dementia - Drug Profile 92 ASN-561 - Drug Profile 93 AVP-786 - Drug Profile 94 AZP-2006 - Drug Profile 97 BAN-0805 - Drug Profile 99 BI-409306 - Drug Profile 100 CB-2233 - Drug Profile 102 CB-8411 - Drug Profile 103 choline alfoscerate SR - Drug Profile 104 D-217 - Drug Profile 105 dehydroevodiamine hydrochloride - Drug Profile 106 Drugs for Dementia - Drug Profile 107 Drugs to Agonize Hepatocyte Growth Factor Receptor for Dementia - Drug Profile 108 Drugs to Inhibit Matrix Metalloproteinase for Dementia and Cognitive Impairment - Drug Profile 109 DWJ-1365 - Drug Profile 110 E-2609 - Drug Profile 111 eltoprazine - Drug Profile 113 encenicline hydrochloride - Drug Profile 118 FRM-0334 - Drug Profile 123 GIBH-130 - Drug Profile 125 Gln-1062 - Drug Profile 126 GTC-6000 - Drug Profile 129 gugulipid - Drug Profile 130 HOB-075 - Drug Profile 131 HTL-18318 - Drug Profile 132 intepirdine - Drug Profile 133 INV-331 - Drug Profile 135 IRL-752 - Drug Profile 136 ITI-007 - Drug Profile 137 levetiracetam - Drug Profile 145 LUAF-20513 - Drug Profile 147 MM-201 - Drug Profile 148 Monoclonal Antibodies for Alzheimer's Disease and Vascular Dementia - Drug Profile 149 Monoclonal Antibodies for Dementia and Alzheimer's Disease - Drug Profile 150 Monoclonal Antibodies to Inhibit Tau for CNS Disorders - Drug Profile 151 monosodium luminol - Drug Profile 152 NAT - Drug Profile 154 nelotanserin - Drug Profile 155 Neurostem - Drug Profile 157 NI-205 - Drug Profile 159 NI-308 - Drug Profile 160 NNC-269100 - Drug Profile 161 NP-001 - Drug Profile 162 ORY-2001 - Drug Profile 165 P-003 - Drug Profile 167 PD-2015 - Drug Profile 168 PD-2016 - Drug Profile 169 PD-2024 - Drug Profile 170 PD-2244 - Drug Profile 171 Peptide to Inhibit BACE for Cerebropathy and Dementia - Drug Profile 172 PST-900 - Drug Profile 173 salicylamine - Drug Profile 174 SIN-1502 - Drug Profile 175 Small Molecule for Dementia - Drug Profile 176 Small Molecule to Activate ABC Transporter for Neurodegeneration Disorders - Drug Profile 177 Small Molecule to Activate LPL for CNS and Metabolic Disorders - Drug Profile 178 Small Molecule to Inhibit Glycogene 5 for Dementia - Drug Profile 179 Small Molecules for Frontotemporal Dementia - Drug Profile 180 Small Molecules for Ophthalmology and CNS Disorders - Drug Profile 181 Small Molecules to Agonize HGFR for CNS Disorders - Drug Profile 182 Small Molecules to Agonize M1 Muscarinic Acetylcholine Receptor for Lewy Body Dementia and Parkinson's Disease Dementia - Drug Profile 183 Small Molecules to Inhibit TANA for ALS, Alzheimer's Disease and Dementia - Drug Profile 184 SND-14 - Drug Profile 185 SYN-120 - Drug Profile 186 Synthetic Peptides to Activate PACAP Receptor and Antagonize VPAC1, VPAC2 for Neurological Disorders - Drug Profile 188 TAK-070 - Drug Profile 189 TAK-071 - Drug Profile 190 TauC-3 - Drug Profile 191 tolfenamic acid - Drug Profile 192 TPI-287 - Drug Profile 193 TRx-0237 - Drug Profile 197 TTT-3002 - Drug Profile 201 VYTAU-01 - Drug Profile 202 WIB-1001C - Drug Profile 203 zonisamide - Drug Profile 204 Dementia - Dormant Projects 206 Dementia - Discontinued Products 211 Dementia - Product Development Milestones 212 Featured News & Press Releases 212 Appendix 226 Methodology 226 Coverage 226 Secondary Research 226 Primary Research 226 Expert Panel Validation 226 Contact Us 226 Disclaimer 227
List of Tables
Number of Products under Development for Dementia, H2 2016 17 Number of Products under Development for Dementia - Comparative Analysis, H2 2016 18 Number of Products under Development by Companies, H2 2016 19 Number of Products under Development by Companies, H2 2016 (Contd..1) 20 Number of Products under Development by Companies, H2 2016 (Contd..2) 21 Number of Products under Investigation by Universities/Institutes, H2 2016 22 Comparative Analysis by Late Stage Development, H2 2016 23 Comparative Analysis by Clinical Stage Development, H2 2016 24 Comparative Analysis by Early Stage Development, H2 2016 25 Comparative Analysis by Unknown Stage Development, H2 2016 26 Products under Development by Companies, H2 2016 27 Products under Development by Companies, H2 2016 (Contd..1) 28 Products under Development by Companies, H2 2016 (Contd..2) 29 Products under Development by Companies, H2 2016 (Contd..3) 30 Products under Investigation by Universities/Institutes, H2 2016 31 Dementia - Pipeline by Adamas Pharmaceuticals, Inc., H2 2016 32 Dementia - Pipeline by AgeneBio Inc., H2 2016 33 Dementia - Pipeline by Alector LLC, H2 2016 34 Dementia - Pipeline by AlzProtect SAS, H2 2016 35 Dementia - Pipeline by Amarantus Bioscience Holdings, Inc., H2 2016 36 Dementia - Pipeline by Anavex Life Sciences Corp., H2 2016 37 Dementia - Pipeline by Axon Neuroscience SE, H2 2016 38 Dementia - Pipeline by Axovant Sciences Ltd., H2 2016 39 Dementia - Pipeline by BioArctic Neuroscience AB, H2 2016 40 Dementia - Pipeline by Biogen Inc, H2 2016 41 Dementia - Pipeline by Biotie Therapies Corp., H2 2016 42 Dementia - Pipeline by Boehringer Ingelheim GmbH, H2 2016 43 Dementia - Pipeline by Chase Pharmaceuticals Corporation, H2 2016 44 Dementia - Pipeline by Cortice Biosciences, Inc., H2 2016 45 Dementia - Pipeline by Daewoong Pharmaceutical Co., Ltd., H2 2016 46 Dementia - Pipeline by Eisai Co., Ltd., H2 2016 47 Dementia - Pipeline by Eli Lilly and Company, H2 2016 48 Dementia - Pipeline by FORUM Pharmaceuticals Inc., H2 2016 49 Dementia - Pipeline by H. Lundbeck A/S, H2 2016 50 Dementia - Pipeline by Heptares Therapeutics Limited, H2 2016 51 Dementia - Pipeline by Hyundai Pharmaceutical Co., Ltd., H2 2016 52 Dementia - Pipeline by Ildong Pharmaceutical Co., Ltd., H2 2016 53 Dementia - Pipeline by Immungenetics AG, H2 2016 54 Dementia - Pipeline by ImStar Therapeutics Inc., H2 2016 55 Dementia - Pipeline by Integrative Research Laboratories Sweden AB, H2 2016 56 Dementia - Pipeline by Intellect Neurosciences, Inc., H2 2016 57 Dementia - Pipeline by Intra-Cellular Therapies, Inc., H2 2016 58 Dementia - Pipeline by INVENT Pharmaceuticals, Inc., H2 2016 59 Dementia - Pipeline by M3 Biotechnology, Inc., H2 2016 60 Dementia - Pipeline by MediPost Co., Ltd., H2 2016 61 Dementia - Pipeline by Neuraltus Pharmaceuticals, Inc., H2 2016 62 Dementia - Pipeline by Neurimmune Holding AG, H2 2016 63 Dementia - Pipeline by Neurodyn Inc., H2 2016 64 Dementia - Pipeline by Oryzon Genomics SA, H2 2016 65 Dementia - Pipeline by Otsuka Holdings Co., Ltd., H2 2016 66 Dementia - Pipeline by P2D Bioscience, H2 2016 67 Dementia - Pipeline by Pacific Northwest Biotechnology, LLC, H2 2016 68 Dementia - Pipeline by Pivot Pharmaceuticals Inc, H2 2016 69 Dementia - Pipeline by Sinil Pharmaceutical Co., Ltd, H2 2016 70 Dementia - Pipeline by Stelic Institute & Co., Inc., H2 2016 71 Dementia - Pipeline by Sumitomo Dainippon Pharma Co., Ltd., H2 2016 72 Dementia - Pipeline by Sylentis S.A.U., H2 2016 73 Dementia - Pipeline by Takeda Pharmaceutical Company Limited, H2 2016 74 Dementia - Pipeline by TauRx Therapeutics Ltd., H2 2016 75 Dementia - Pipeline by Voyager Therapeutics, Inc., H2 2016 76 Dementia - Pipeline by WhanIn Pharmaceutical Co., Ltd., H2 2016 77 Dementia - Pipeline by Zhejiang Hisun Pharmaceutical Co., Ltd., H2 2016 78 Assessment by Monotherapy Products, H2 2016 79 Assessment by Combination Products, H2 2016 80 Number of Products by Stage and Target, H2 2016 82 Number of Products by Stage and Mechanism of Action, H2 2016 85 Number of Products by Stage and Route of Administration, H2 2016 88 Number of Products by Stage and Molecule Type, H2 2016 90 Dementia - Dormant Projects, H2 2016 212 Dementia - Dormant Projects (Contd..1), H2 2016 213 Dementia - Dormant Projects (Contd..2), H2 2016 214 Dementia - Dormant Projects (Contd..3), H2 2016 215 Dementia - Dormant Projects (Contd..4), H2 2016 216 Dementia - Discontinued Products, H2 2016 217
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
